Evidence map›Paper›PMID 37901513›Full record

ArticleACS omega2023

Poloxamer 407 Combined with Polyvinylpyrrolidone To Prepare a High-Performance Poly(ether sulfone) Ultrafiltration Membrane.

Zhijiang Sun, Zehua Yin, Mingyu Zhang, Dongli Guo, Fen Ran

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Zhijiang SunState Key Laboratory of Advanced Processing and Recycling of Non-ferrous Metals, School of Materials Science and Engineering, Lanzhou University of Technology, Lanzhou 730050, PR China.
Zehua YinJiangsu Solicitude Medical Technology co., Ltd., Suzhou 215100, PR China.
Mingyu ZhangState Key Laboratory of Advanced Processing and Recycling of Non-ferrous Metals, School of Materials Science and Engineering, Lanzhou University of Technology, Lanzhou 730050, PR China.
Dongli GuoState Key Laboratory of Advanced Processing and Recycling of Non-ferrous Metals, School of Materials Science and Engineering, Lanzhou University of Technology, Lanzhou 730050, PR China.
Fen RanState Key Laboratory of Advanced Processing and Recycling of Non-ferrous Metals, School of Materials Science and Engineering, Lanzhou University of Technology, Lanzhou 730050, PR China.ORCID https://orcid.org/0000-0002-7383-1265
Lanzhou University of Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

At present, the design and fabrication of polymer membranes with high permeability and good retention ability are still huge challenges. In this study, the commercial Poloxamer 407 (Pluronic F127) is selected as a multifunctional additive, and polyvinylpyrrolidone is used as a pore-forming agent to modify the poly(ether sulfone) membrane by liquid-liquid phase conversion technology to prepare an ultrafiltration membrane with excellent performance. The hydrophobic poly(propylene oxide) segment in Poloxamer 407 guarantees that this copolymer can be firmly anchored to the poly(ether sulfone) matrix, and the hydrophilic poly(ethylene oxide) segments in Poloxamer 407 impart a stronger hydrophilic nature to the modified membrane surface. Therefore, the permeability and hydrophilicity of the modified membrane are significantly improved and the modified membrane also has good stability. When the amount of Poloxamer 407 added to the casting solution reached 0.6 g, the water flux of the modified membrane was as high as 368 L m

Identifiers

PMID37901513
PMCPMC10600910
OpenAlexW4387539115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.